Summary
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
History
Halozyme Therapeutics was founded by Howard Birndorf and Harvey Berger in 1998. The company was established to develop proprietary technologies to increase the performance of biologic and small-molecule drugs in the pharmaceutical and biotech markets. Since its inception, Halozyme has developed a range of proprietary technologies, including Enhanze®, its rHuPH20 development platform, and Accent® delivery and solubility technology.
Mission
Our mission is to develop and deliver innovative medicines that improve the lives of people suffering from cancer, immune disorders and other disabling conditions.
Vision
Our vision is to be the world leader in developing and delivering innovative medicines that improve the lives and enhance the overall quality of care of people with cancer, immune disorders, rare diseases, and other disabling conditions.
Key Team
Ms. Tram Bui (VP of Investor Relations & Corp. Communications)
Mr. Mark Snyder Esq. (Gen. Counsel, Chief Compliance Officer & Corp. Sec.)
Mr. Todd Butler (Chief of Staff to the CEO, VP & Head of Project Management)
Ms. Amy Marinne Fox (Chief HR Officer)
Dr. Christopher Bryant Ph.D. (Chief Manufacturing Officer & Head of Technical Operations)
Dr. Steve Knowles MBBS (Chief Medical Officer)
Recognition and Awards
Halozyme has been recognized as one of the best companies to work for and has been honored with numerous awards including Deloitte & Touche’s Technology Fast 500, Ernst & Young’s Entreneur of the Year, and National Institutes of Health Tech Transfer Award.
References
United States 